Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red de Cáncer (14)

2023

  1. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2021

  1. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?

    Frontiers in Cell and Developmental Biology, Vol. 9

  2. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Genetic mouse models as in vivo tools for cholangiocarcinoma research

    Cancers, Vol. 11, Núm. 12

  3. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  4. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

    Drug Safety, Vol. 42, Núm. 2, pp. 281-294

  5. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Revisiting interleukin-12 as a cancer immunotherapy agent

    Clinical Cancer Research, Vol. 24, Núm. 12, pp. 2716-2718

2017

  1. Interleukin-8 in cancer pathogenesis, treatment and follow-up

    Cancer Treatment Reviews, Vol. 60, pp. 24-31